Opko Health (NYSE:OPK) announced Tuesday that its finance head, Juan Rodriguez, will step down to pursue other business interests but will continue to provide services in a consulting capacity.
The biopharmaceutical company promoted chief accounting officer, Adam Logal, to chief financial officer on the heels of the move.
"Adam has been a key leader in our organization since our inception in 2007,” Opko CEO Phillip Frost said in a statement, adding that Logal will help lead the company through "near term commercial opportunities."
Logal most recently served as vice president of finance, chief account officer and treasurer
Meanwhile, the Miami-based drug manufacturer appointed Arie Gutman to CEO of its active pharmaceutical ingredient and chemical development division.
Gutman is the founder of FineTech Pharmaceutical, an FDA-approved business specializing in the development and manufacture of complex active pharmaceutical ingredients, which Opko acquired in December 2011. He has led several successful launches of specialty generic drugs.
In his new role, he will lead efforts to develop additional chemistry-based and advanced synthetic businesses for Opko’s internal drug and diagnostic development programs.
Shares of Opko traded up 0.75% to $9.39 in recent trade.